title: Health care utilization determined from administrative claims analysis for patients who received inhaled corticosteroids with either montelukast or salmeterol.
authors.forename: Leona E
authors.initials: LE
authors.lastname: Markson
authors.forename: Don A A
authors.initials: DA
authors.lastname: Bukstein
authors.forename: Allan T
authors.initials: AT
authors.lastname: Luskin
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003521:Cyclopropanes; D003695:Delivery of Health Care / Q000706:statistics & numerical data*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004363:Drug Utilization; D004632:Emergency Medical Services / Q000706:statistics & numerical data; D006760:Hospitalization; D006801:Humans; D007345:Insurance Claim Review; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068299:Salmeterol Xinafoate; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000068299:Salmeterol Xinafoate; C093875:montelukast; D000420:Albuterol